There are 511 resources available
171P - A phase II study of ABSK-011 plus atezolizumab in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Xiao-Ping Chen
Session: Poster Display session
Resources:
Abstract
172P - TACE combined with tislelizumab and TKI as a conversion therapy in initial unresectable hepatocellular carcinoma (uHCC): A prospective single-arm phase II clinical study
Presenter: Shaoping Liu
Session: Poster Display session
Resources:
Abstract
173P - A phase II trial of donafenib plus sintilimab for advanced stage hepatocellular carcinoma
Presenter: Mingyue Cai
Session: Poster Display session
Resources:
Abstract
174P - A single-arm open-label pilot study of combination therapy of TACE in combination with ablation and durvalumab in unresectable hepatocellular carcinoma patients (TAD study)
Presenter: Bei Tang
Session: Poster Display session
Resources:
Abstract
175P - Tislelizumab plus hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT): A prospective, signal-arm, phase II clinical study
Presenter: HAIBIN ZHANG
Session: Poster Display session
Resources:
Abstract
176P - Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma
Presenter: Hong Jae Chon
Session: Poster Display session
Resources:
Abstract
177P - Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A meta-analysis and systematic review
Presenter: Wei Zhang
Session: Poster Display session
Resources:
Abstract
178P - Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: An updated meta-analysis and meta-regression of observational studies
Presenter: Mahmoud Abdelgalil
Session: Poster Display session
Resources:
Abstract
179P - Transarterial chemoembolization plus lenvatinib with or without immune checkpoint inhibitors for advanced hepatocellular carcinoma: A meta-analysis and systematic review
Presenter: Wei Zhang
Session: Poster Display session
Resources:
Abstract
180P - A systematic review with meta-analysis of risks and benefits of tyrosine kinase inhibitors in hepatocellular carcinoma treatment
Presenter: Jennifer Martínez-Geijo
Session: Poster Display session
Resources:
Abstract